Xiang Zhou, Annika Hofmann, Benedict Engel, Cornelia Vogt, Silvia Nerreter, Yoko Tamamushi, Friederike Schmitt, Maria leberzammer, Emilia Stanojkovska, Marietta Truger, Xianghui Xiao, Christine Riedhammer, Maximilian J. Steinhardt, Mara John, Julia Mersi, Seungbin Han, Umair Munawar, Johannes M. Waldschmidt, Claudia Haferlach, Hermann Einsele, Leo Rasche, K. Martin Kortüm
{"title":"Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma","authors":"Xiang Zhou, Annika Hofmann, Benedict Engel, Cornelia Vogt, Silvia Nerreter, Yoko Tamamushi, Friederike Schmitt, Maria leberzammer, Emilia Stanojkovska, Marietta Truger, Xianghui Xiao, Christine Riedhammer, Maximilian J. Steinhardt, Mara John, Julia Mersi, Seungbin Han, Umair Munawar, Johannes M. Waldschmidt, Claudia Haferlach, Hermann Einsele, Leo Rasche, K. Martin Kortüm","doi":"10.1002/hem3.70078","DOIUrl":null,"url":null,"abstract":"<p>The definition of high-risk (HR) multiple myeloma (MM) is still a matter of debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling in 258 MM patients (newly diagnosed [ND] MM: <i>n</i> = 109; relapsed/refractory [RR] MM: <i>n</i> = 149). HR SKY92 was significantly enriched in RRMM (57/121, 47.1%) compared with NDMM (17/95, 17.9%) (<i>p</i> < 0.0001). RRMM patients with HR SKY92 showed significantly shorter progression-free survival (PFS) (<i>p</i> < 0.0001) and overall survival (OS) (<i>p</i> < 0.0001) than SKY92 standard-risk (SR). In NDMM, HR SKY92 also indicated a significantly inferior PFS (<i>p</i> < 0.0001) in comparison with SR. We combined SKY92 with FISH (HR: t(4;14), del17p, +1q21 according to R2-ISS) in 181 patients (NDMM: <i>n</i> = 79; RRMM: <i>n</i> = 102). We found a discrepancy between both risk stratification systems, with only 49 (27.1%) patients being defined as HR by both SKY92 and FISH (“double HR”). In terms of survival outcomes, “double HR” presented a negative prognostic factor for PFS in both NDMM (<i>p</i> < 0.0001) and RRMM (<i>p</i> < 0.0001). Furthermore, “double-HR” patients showed the worst OS (<i>p</i> = 0.000 13) in RRMM. Additionally, whole genome sequencing (WGS) revealed <i>CRBN</i> mutation (<i>n</i> = 3) and bi-allelic events (mutation and/or deletion) in <i>TP53</i> (<i>n</i> = 7) and <i>TNFRSF17</i> (<i>n</i> = 1). Altogether, we provide the first prospective real-world evidence that the combination SKY92 and FISH (according to R2-ISS) identifies a subset of patients with ultra-HR MM, and WGS complements SKY92 and FISH in MM risk stratification.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.70078","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The definition of high-risk (HR) multiple myeloma (MM) is still a matter of debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling in 258 MM patients (newly diagnosed [ND] MM: n = 109; relapsed/refractory [RR] MM: n = 149). HR SKY92 was significantly enriched in RRMM (57/121, 47.1%) compared with NDMM (17/95, 17.9%) (p < 0.0001). RRMM patients with HR SKY92 showed significantly shorter progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001) than SKY92 standard-risk (SR). In NDMM, HR SKY92 also indicated a significantly inferior PFS (p < 0.0001) in comparison with SR. We combined SKY92 with FISH (HR: t(4;14), del17p, +1q21 according to R2-ISS) in 181 patients (NDMM: n = 79; RRMM: n = 102). We found a discrepancy between both risk stratification systems, with only 49 (27.1%) patients being defined as HR by both SKY92 and FISH (“double HR”). In terms of survival outcomes, “double HR” presented a negative prognostic factor for PFS in both NDMM (p < 0.0001) and RRMM (p < 0.0001). Furthermore, “double-HR” patients showed the worst OS (p = 0.000 13) in RRMM. Additionally, whole genome sequencing (WGS) revealed CRBN mutation (n = 3) and bi-allelic events (mutation and/or deletion) in TP53 (n = 7) and TNFRSF17 (n = 1). Altogether, we provide the first prospective real-world evidence that the combination SKY92 and FISH (according to R2-ISS) identifies a subset of patients with ultra-HR MM, and WGS complements SKY92 and FISH in MM risk stratification.
高风险(HR)多发性骨髓瘤(MM)的定义仍然是一个争论的问题。我们对258名MM患者(新诊断的[ND] MM: n = 109;复发/难治性[RR] MM: n = 149)。与NDMM(17/95, 17.9%)相比,HR SKY92在RRMM(57/121, 47.1%)中显著富集(p p p p n = 79;RRMM: n = 102)。我们发现两种风险分层系统之间存在差异,只有49例(27.1%)患者同时被SKY92和FISH定义为高危人群(“双高危人群”)。在生存结局方面,“双HR”是两种NDMM患者PFS的负面预后因素(p p p = 0.000 13)。此外,全基因组测序(WGS)揭示了TP53 (n = 7)和TNFRSF17 (n = 1)的CRBN突变(n = 3)和双等位基因事件(突变和/或缺失)。总之,我们提供了第一个前瞻性的现实世界证据,即SKY92和FISH联合(根据R2-ISS)识别出一组超hr MM患者,WGS补充了SKY92和FISH在MM风险分层中的作用。
期刊介绍:
HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology.
In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care.
Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.